Daily Lifestyle and Cutaneous Malignancies

Sawada, Yu; Nakamura, Motonobu

doi:10.3390/ijms22105227

Cited by 14 publications

(11 citation statements)

References 170 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2018, there were 1,042,056 diagnosed cases and 65,155 deaths worldwide [ 1 ]. The incidence of this type of tumor is increasing in both older people, due to lengthening life expectancy, and in younger people, as a result of greater exposure to the sun and other behavioral changes [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

High-dose-rate plesiotherapy with customized molds in non-melanoma skin cancer: efficacy and safety at 10 years—single institution experience

et al. 2021

View full text Add to dashboard Cite

Purpose Our center adopted high-dose-rate brachytherapy with surface applicators (plesiotherapy) in 2008, creating custom molds to treat irregular areas. This study describes the efficacy and safety outcomes after extensive follow-up in the patients. Methods/patients We planned the treatment using two computed tomography (CT) scans: the first to delineate the lesion and the second after placing the thermoplastic mold. Fusing the two CT images enables planning of the target volume and pinpointing, where the catheters are in the mold. Results Seventy patients received plesiotherapy, either exclusively or following excision in patients with risk factors for recurrence. Those receiving plesiotherapy alone showed a complete response rate of 95.8%, and recurrences occurred in 5.7% at a mean follow-up of 96.2 months. Chronic toxicity appeared in 26.6% of patients, but severity was limited to grade 1 or 2. Conclusions High-dose-rate brachytherapy with customized molds yields a high rate of complete response, with long-term recurrence rates in line with similar studies and an acceptable toxicity rate.

show abstract

Section: Introductionmentioning

confidence: 99%

High-dose-rate plesiotherapy with customized molds in non-melanoma skin cancer: efficacy and safety at 10 years—single institution experience

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Cutaneous squamous cell carcinoma is a skin cancer derived from epithelial keratinocytes, and its advanced form has an unfavorable clinical course because of the limited number of therapeutic options in the current treatment [ 56 , 57 , 58 ]. In addition, immune checkpoint inhibitor treatment is not widely used for treating metastatic cutaneous squamous cell carcinoma.…”

Section: Sting-involved Anti-tumor Immunitymentioning

confidence: 99%

STING Signaling and Skin Cancers

Sato

Sawada

Nakamura

2021

Cancers

Self Cite

View full text Add to dashboard Cite

Recent developments in immunotherapy against malignancies overcome the disadvantages of traditional systemic treatments; however, this immune checkpoint treatment is not perfect and cannot obtain a satisfactory clinical outcome in all cases. Therefore, an additional therapeutic option for malignancy is needed in oncology. Stimulator of interferon genes (STING) has recently been highlighted as a strong type I interferon driver and shows anti-tumor immunity against various malignancies. STING-targeted anti-tumor immunotherapy is expected to enhance the anti-tumor effects and clinical outcomes of immunotherapy against malignancies. In this review, we focus on recent advancements in the knowledge gained from research on STING signaling in skin cancers. In addition to the limitations of STING-targeted immunotherapy, we also discuss the clinical application of STING agonists in the treatment of skin cancer.

show abstract

“…Moreover, dietary regimens have also attracted attention for reducing melanoma risk. Several antioxidant phytochemicals from vegetables and fruits, for example, have demonstrated chemopreventive properties, whereas alcohol intake can increase the risk of malignancy [9,10]. The role of vitamin D in the management of melanoma should also be highlighted, due to its antiproliferative effects.…”

Section: Introductionmentioning

confidence: 99%

The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval

Matias

Pinho

Penetra

et al. 2021

Cells

View full text Add to dashboard Cite

Melanoma is recognized as the most dangerous type of skin cancer, with high mortality and resistance to currently used treatments. To overcome the limitations of the available therapeutic options, the discovery and development of new, more effective, and safer therapies is required. In this review, the different research steps involved in the process of antimelanoma drug evaluation and selection are explored, including information regarding in silico, in vitro, and in vivo experiments, as well as clinical trial phases. Details are given about the most used cell lines and assays to perform both two- and three-dimensional in vitro screening of drug candidates towards melanoma. For in vivo studies, murine models are, undoubtedly, the most widely used for assessing the therapeutic potential of new compounds and to study the underlying mechanisms of action. Here, the main melanoma murine models are described as well as other animal species. A section is dedicated to ongoing clinical studies, demonstrating the wide interest and successful efforts devoted to melanoma therapy, in particular at advanced stages of the disease, and a final section includes some considerations regarding approval for marketing by regulatory agencies. Overall, considerable commitment is being directed to the continuous development of optimized experimental models, important for the understanding of melanoma biology and for the evaluation and validation of novel therapeutic strategies.

show abstract

Daily Lifestyle and Cutaneous Malignancies

Cited by 14 publications

References 170 publications

High-dose-rate plesiotherapy with customized molds in non-melanoma skin cancer: efficacy and safety at 10 years—single institution experience

High-dose-rate plesiotherapy with customized molds in non-melanoma skin cancer: efficacy and safety at 10 years—single institution experience

STING Signaling and Skin Cancers

The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval

Contact Info

Product

Resources

About